Bain Capital will partner with Milacron’s current owner, Hillenbrand, Inc. (NYSE: HI), who will remain a significant investor in the business to accelerate the Company’s continued growth.

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Bain Capital now majority owner of Milacron Transaction enhances Hillenbrand's focus on core business Net proceeds to be used to reduce debt BATESVILLE, Ind., March 31, 2025 /PRNewswire ...

Hillenbrand, Inc. HI announced that it has completed the previously announced sale of its majority interest in the Milacron injection molding and extrusion business (or Milacron) to Bain Capital ...

Milacron is an injection molding and extrusion business. Photo: Lubos Pavlicek/Zuma Press Hillenbrand has sold a majority stake in Milacron to an affiliate of Bain Capital Special Situations.

BOSTON & BATESVILLE, Ind., February 05, 2025--Bain Capital, a leading private investment firm, today announced a majority investment in the Milacron Injection Molding and Extrusion business (or the ...